The impact of iron overload and its treatment on quality of life: Results from a literature review

Health and Quality of Life Outcomes

Volumn 4, Issue , 2006, Pages

  Abetz, Linda ^a   Baladi, Jean Francois ^b   Jones, Paula ^b   Rofail, Diana ^a  

^a MAPI VALUES   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; SIDEROPHORE;

ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DATA BASE; DEPRESSION; DISTRESS SYNDROME; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; HEALTH ECONOMICS; HOSPITALIZATION; HUMAN; INFORMATION PROCESSING; INTERVIEW; IRON OVERLOAD; MEDICAL DOCUMENTATION; MEDICAL EXPERT; MEDICAL LITERATURE; MEDLINE; MYELODYSPLASTIC SYNDROME; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PUBLISHING; QUALITATIVE ANALYSIS; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; SICKLE CELL ANEMIA; SURVIVAL RATE; THALASSEMIA; CHELATION THERAPY; PATHOPHYSIOLOGY; PATIENT CARE; PSYCHOLOGICAL ASPECT; REVIEW; SICKNESS IMPACT PROFILE; TREATMENT OUTCOME;

CHELATION THERAPY; DEFEROXAMINE; EPISODE OF CARE; HUMANS; IRON OVERLOAD; QUALITY OF LIFE; SICKNESS IMPACT PROFILE; SIDEROPHORES; TREATMENT OUTCOME;

EID: 33750440169     PISSN: 14777525     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-4-73     Document Type: Article

References (32)

1. Gabutti V, Borgna-Pignatti C: Clinical manifestations and therapy of transfusional haemosiderosis. Baillieres Clin Haematol 1994, 7:919-940.
2. Ratip S, Skuse D, Porter J, Wonke B, Yardumian A, Modell B: Psychosocial and clinical burden of thalassaemia intermedia and its implications for prenatal diagnosis. Arch Dis Child 1995, 72:408-412.
3. Caro JJ, Ward A, Green TC, Huybrechts K, Arana A, Wait S, Eleftheriou A: Impact of thalassemia major on patients and their families. Acta Haematologica 2002, 107:150-157.
4. Rebulla P: Transfusion reac tions in thalassemia. A survey from the Cooleycare programme. The Cooleycare Cooperative Group. Haematologica 1990, 75:122-127.
5. Giardina PJ, Grady RW: Chelation therapy in beta-thalassemia: an optimistic update. Seminars in Hematology 2001, 38:360-366.
6. Alymara V, Bourantas D, Chaidos A, Bouranta P, Gouva M, Vassou A, Tzouvara E, Bourantas KL: Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone. Hematology Journal 5(6):475-9, 2004.
7. Gabutti V, Piga A: Results of long-term iron-chelating therapy. [Review] [109 refs]. Acta Haematologica 1996, 91:26-36.
8. Porter JB: Deferoxamine pharmacokinetics. Semin Hematol 2001, 38:63-68.
9. Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty Al, Taher A: Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol 2003, 121:187-189.
10. Piga A:. Bone Marrow Transplant 2001, 19:11-13.
11. Shumaker SA, Berzon RA: The international assessment of HRQL. Theory, translations, measurement and analysis. Oxford: Rapid Communications; 1995.
12. Bowling A: Current state of the art in quality of life measurement. In Quality of life Edited by: Carr AJ, Higginson IJ and Robinson P. London, BMJ Books; 2003.
13. Clarke S, Eiser C: The measurement of health-related quality of life (QOL) in pediatric trials: a systemic review. 2004, 6:66.
14. Tefler P, Constantinidou G, Andreou P, Christou S, Modell B, Angastiniotis M: Quality of Life in Thalassaemia. Annals of the New York Academy of Science 2005, 1054:273-282.
15. Pakbaz Z, Treadwell M, Yamashita R, Quirolo K, Foote D, Quill L, Singer T, Vichinsky EP: Quality of Life in Patients with Thalassaemia Intermedia Compared to Thalassaemia Major. New York Academy of Sciences 2005, 1054:457-461.
16. Ismail A, Campbell MJ, Ibrahim HS, Jones GL: Health related quality of life in Malaysian children with thalassaemia. Health and Quality of Life Outcomes 2006, 4:39.
17. Anie KA, Steptoe A, Bevan DH: Sickle cell disease: Pain, coping and quality of life in a study of adults in the UK. Br J Health Psychol 2002, 7:331-344.
18. Cummins O, Anie KA: A comparison of the outcome of cognitive behaviour therapy and hydroxyurea in sickle cell disease. Psychol Health Med 2003, 8:199-204.
19. Fuggle P, Shand PA, Gill LJ, Davies SC: Pain, quality of life, and coping in sickle cell disease. Arch Dis Child 1996, 75:199-203.
20. Hasan SP, Hashmi S, Alhassen M, Lawson W, Castro O: Depression in sickle cell disease. Journal of the National Medical Association 2003, 95:533-537.
21. Palermo TM, Schwartz L, Drotar D, McGowan K: Parental report of health-related quality of life in children with sickle cell disease. J Behav Med 2002, 25:269-283.
22. Thomas VJ, Hambleton I, Serjeant G: Psychological distress and coping in sickle cell disease: comparison of British and Jamaican attitudes. Ethn Health 2001, 6:129-136.
23. Thomas VJ, Taylor LM: The psychosocial experience of people with sickle cell disease and its impact on quality of life: Qualitative findings from focus groups. Br J Health Psychol 2002, 7:345-363.
24. Jansen AJ, Essink-Bot ML, Beckers EA, Hop WC, Schipperus MR, Van Rhenen DJ: Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. Br J Haematol 2003, 121:270-274.
25. Kornblith AB, Herndon JE, Silverman LR, Demakos EP, Odchimar-Reissig R, Holland JF, Powell BL, DeCastro C, Ellerton J, Larson RA, Schiffer CA, Holland JC: Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. Journal of Clinical Oncology 2002:2441-2452.
26. Sekeres MA, Stone RM, Zahrieh D, Neuberg D, Morrison V, De Angelo DJ, Galinsky I, Lee SJ: Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 2004, 18:809-816.
27. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002, 20:2429-2440.
28. Arboretti R, Tognoni G, Alberti D, Thalassarmia ICG: Pharmaco-surveillance and quality of care of thalassaemic patients. A large scale epidemiological survey. European Journal of Clinical Pharmacology 2001, 56:915-922.
29. Smiley M: Beta thalassaemia in Papua New Guinea. Ann Trop Paediatr 1986, 6:175-177.
30. Basran RK, Fasson FF, Shaw D, Olivieri NF: Assessment of the relative quality of life in patients receiving subcutaneous deferoxamine and the orally active iron chelating agent LI. Blood 1994, 84:261a.
31. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Capra M, Galanello R, Fattoum S, Drelichman G, Magnano C, Verissimo M, Athanassiou-Metaxa M, Giardina P, Kourakli-Symeonidis A, Janka-Schaub G, Coates T, Vermylen C, Olivieri N, Thuret I, Opitz H, Ressayre-Djaffer C, Marks P, Alberti D: A Phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with {beta}-thalassemia. Blood 2005,.
32. Poole JE, Cohn RJ, Roode H, Spector I: Beta-thalassaemia - the Johannesburg experience. S Afr Med J 1989, 75:367-370.